国际生物制品学杂志
國際生物製品學雜誌
국제생물제품학잡지
INTERNATIONAL JOURNAL OF BIOLOGICALS
2008年
6期
241-244,248
,共5页
赵国雄%许文香%周伟忠%杜琳%陈昌标%曾明
趙國雄%許文香%週偉忠%杜琳%陳昌標%曾明
조국웅%허문향%주위충%두림%진창표%증명
志贺菌,宋氏%疫苗,结合%安全性%免疫原性
誌賀菌,宋氏%疫苗,結閤%安全性%免疫原性
지하균,송씨%역묘,결합%안전성%면역원성
Shigella sonnei%Vaccine,conjugate%Safety%Immunogenicity
目的 观察宋内菌痢疾结合疫苗临床安全性和免疫原性.方法按随机、双盲原则,以宋内菌痢疾结合疫苗为试验组,磷酸缓冲盐水为安慰剂对照组,进行临床安全性及免疫原性观察,比较试验组和对照组免疫后临床反应率、抗体阳转率和几何平均滴度(GMT)水平.结果宋内菌痢疾结合疫苗接种后无严重全身反应和局部反应,与对照组比较,差异无统计学意义.试验组经2针全程免疫后2周和12周,抗体阳转率分别为87.46%和82.32%;GMT分别为1∶3250.12和1∶2432.76;抗宋内菌脂多糖(LPS)-IgG抗体滴度较免前平均增长倍数分别为10.7374和8.0353.全程免疫后试验组与对照组之间抗体阳转率、GMT、抗体滴度平均增长倍数比较,差异均有统计学意义.结论宋内菌痢疾结合疫苗具有较好的安全性和免疫原性.
目的 觀察宋內菌痢疾結閤疫苗臨床安全性和免疫原性.方法按隨機、雙盲原則,以宋內菌痢疾結閤疫苗為試驗組,燐痠緩遲鹽水為安慰劑對照組,進行臨床安全性及免疫原性觀察,比較試驗組和對照組免疫後臨床反應率、抗體暘轉率和幾何平均滴度(GMT)水平.結果宋內菌痢疾結閤疫苗接種後無嚴重全身反應和跼部反應,與對照組比較,差異無統計學意義.試驗組經2針全程免疫後2週和12週,抗體暘轉率分彆為87.46%和82.32%;GMT分彆為1∶3250.12和1∶2432.76;抗宋內菌脂多糖(LPS)-IgG抗體滴度較免前平均增長倍數分彆為10.7374和8.0353.全程免疫後試驗組與對照組之間抗體暘轉率、GMT、抗體滴度平均增長倍數比較,差異均有統計學意義.結論宋內菌痢疾結閤疫苗具有較好的安全性和免疫原性.
목적 관찰송내균이질결합역묘림상안전성화면역원성.방법안수궤、쌍맹원칙,이송내균이질결합역묘위시험조,린산완충염수위안위제대조조,진행림상안전성급면역원성관찰,비교시험조화대조조면역후림상반응솔、항체양전솔화궤하평균적도(GMT)수평.결과송내균이질결합역묘접충후무엄중전신반응화국부반응,여대조조비교,차이무통계학의의.시험조경2침전정면역후2주화12주,항체양전솔분별위87.46%화82.32%;GMT분별위1∶3250.12화1∶2432.76;항송내균지다당(LPS)-IgG항체적도교면전평균증장배수분별위10.7374화8.0353.전정면역후시험조여대조조지간항체양전솔、GMT、항체적도평균증장배수비교,차이균유통계학의의.결론송내균이질결합역묘구유교호적안전성화면역원성.
Objective To evaluate clinical safety and immunogenicity of Shigella sonnei conjugate vaccine. Methods A randomized double-blind study was carried out to evaluate the adverse reaction rate as well as seroconversion rate and antibody GMT of Shigella sonnei conjugate vaccine, using phos-phate buffer saline as control. Results No severe local or systemic adverse reactions were observed af-ter immunization with Shigella sonnei conjugate vaccine. No significant difference was found in the local and systemic adverse reaction rates between trial group and control group. The seroeonversion rates of tri-al group 2 and 12 weeks after the two-close schedule were 87.46% and 82.32% ,respectively, and the an-times,respectively,as compared with those before immunization. The seroconversion rate as well as anti-body GMT and its increasing of trial group were significantly higher than those of control group. Con-clusion Shigella sonnei conjugate vaccine showed good clinical safety and immunogenicity.